Search research articles
Contact Us
Filters
Showing results (221-230 of 265) with videos related to
Page
of 27
Sort By:
JAMA Oncology
|
March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial
Tufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2018
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Diana C West, Masha Kocherginsky, Eva Y Tonsing-Carter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 6, 2014
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer
Roisin M Connolly, Jeffrey P Leal, Matthew P Goetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 27, 2020
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α
James N Ingle, Junmei Cairns, Vera J Suman, et al.
Journal for Immunotherapy of Cancer
|
June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Yi Liu, Jodi M Carter, Yaohua Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara A Walley, Gini F Fleming, et al.
Breast Cancer Research and Treatment
|
November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Cynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
The Journal of Clinical Investigation
|
June 8, 2021
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
Yundong He, Liguo Wang, Ting Wei, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 265) with videos related to
Sort By:
Page
of 27
JAMA Oncology
|
March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial
Tufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2018
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
Diana C West, Masha Kocherginsky, Eva Y Tonsing-Carter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer
Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 6, 2014
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer
Roisin M Connolly, Jeffrey P Leal, Matthew P Goetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 27, 2020
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α
James N Ingle, Junmei Cairns, Vera J Suman, et al.
Journal for Immunotherapy of Cancer
|
June 3, 2026
Spatially resolved single-cell landscape of tumor immunotypes reveals the central role of interferon signaling and plasmacytoid dendritic cells in triple-negative breast cancer
Yi Liu, Jodi M Carter, Yaohua Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara A Walley, Gini F Fleming, et al.
Breast Cancer Research and Treatment
|
November 8, 2017
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F Rimawi, Carmine De Angelis, Alejandro Contreras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Cynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
The Journal of Clinical Investigation
|
June 8, 2021
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
Yundong He, Liguo Wang, Ting Wei, et al.
Page
of 27